Juergen Schanzer

Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition, and Antiseizure Activity of 5-Iodotubercidin Analogues

Bheemarao G. Ugarkar, Jay M. DaRe, Joseph J. Kopcho et al. · Journal of Medicinal Chemistry · 2000 · 111 citations · Full text

Molecular Pharmacology, Inhibitory Activity, Biochemistry +15

A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties

Juergen Schanzer, Katharina Wartha, Rebecca Croasdale et al. · Journal of Biological Chemistry · 2014 · 57 citations · Full text

Human Growth, Targeted Inhibition, Glycobiology +9

Adenosine Kinase Inhibitors. 2. Synthesis, Enzyme Inhibition, and Antiseizure Activity of Diaryltubercidin Analogues

Bheemarao G. Ugarkar, Angelo J. Castellino, Jay M. DaRe et al. · Journal of Medicinal Chemistry · 2000 · 53 citations

Diaryltubercidin Analogues, Pharmaceutical Science, Pharmacotherapy +17

Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition

Rebecca Croasdale, Katharina Wartha, Juergen Schanzer et al. · Archives of Biochemistry and Biophysics · 2012 · 45 citations

Igf-1r–egfr Antibodies, Medicine, Immunology +11

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

Juergen Schanzer, Katharina Wartha, Ekkehard Moessner et al. · mAbs · 2016 · 31 citations · Full text